NASDAQ:AQST - Aquestive Therapeutics Stock Price, News & Analysis

$3.85
-0.19 (-4.70 %)
(As of 08/25/2019 04:00 PM ET)
Today's Range
$3.82
Now: $3.85
$4.1250
50-Day Range
$3.13
MA: $3.93
$4.93
52-Week Range
$2.96
Now: $3.85
$20.70
Volume245,249 shs
Average Volume72,730 shs
Market Capitalization$96.37 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Aquestive Therapeutics, Inc, a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery in the United States and internationally. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AQST
CUSIPN/A
CIKN/A
Phone908-941-1900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$67.43 million
Book Value($0.99) per share

Profitability

Net Income$-61,380,000.00
Net Margins-119.15%

Miscellaneous

Employees277
Market Cap$96.37 million
Next Earnings Date11/5/2019 (Estimated)
OptionableNot Optionable

Receive AQST News and Ratings via Email

Sign-up to receive the latest news and ratings for AQST and its competitors with MarketBeat's FREE daily newsletter.


Aquestive Therapeutics (NASDAQ:AQST) Frequently Asked Questions

What is Aquestive Therapeutics' stock symbol?

Aquestive Therapeutics trades on the NASDAQ under the ticker symbol "AQST."

How were Aquestive Therapeutics' earnings last quarter?

Aquestive Therapeutics Inc (NASDAQ:AQST) announced its quarterly earnings data on Tuesday, August, 6th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.67) by $0.15. The business earned $11.13 million during the quarter, compared to analysts' expectations of $10.46 million. Aquestive Therapeutics had a negative net margin of 119.15% and a negative return on equity of 8,682.29%. View Aquestive Therapeutics' Earnings History.

When is Aquestive Therapeutics' next earnings date?

Aquestive Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, November 5th 2019. View Earnings Estimates for Aquestive Therapeutics.

What price target have analysts set for AQST?

5 brokerages have issued twelve-month price objectives for Aquestive Therapeutics' stock. Their predictions range from $10.00 to $31.00. On average, they anticipate Aquestive Therapeutics' stock price to reach $20.00 in the next year. This suggests a possible upside of 419.5% from the stock's current price. View Analyst Price Targets for Aquestive Therapeutics.

What is the consensus analysts' recommendation for Aquestive Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aquestive Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aquestive Therapeutics.

What are Wall Street analysts saying about Aquestive Therapeutics stock?

Here are some recent quotes from research analysts about Aquestive Therapeutics stock:
  • 1. According to Zacks Investment Research, "Aquestive Therapeutics, Inc. is a specialty pharmaceutical company. It commercializes medicines to solve critical health care problems as well as engages on late-stage proprietary product pipeline which focuses on the treatment of diseases of central nervous system. Aquestive Therapeutics, Inc. is based in NJ, United States. " (8/12/2019)
  • 2. HC Wainwright analysts commented, "We utilize a discounted cash flow (DCF)-based assessment to value Aquestive Therapeutics shares. Using a composite of contributions from Sympazan and Libervant sales along with APL-130277 royalties, plus the impact of legacy revenues from royalties on sales of Suboxone and Zuplenz, we derive a total risk-adjusted net present value (rNPV) of $312M. We employ a discount rate of 15% and effective tax rate of 30%. Our probability of approval for Libervant is 90%, while we utilize a 75% probability of approval for APL-130277." (4/22/2019)

Has Aquestive Therapeutics been receiving favorable news coverage?

News articles about AQST stock have been trending positive this week, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Aquestive Therapeutics earned a daily sentiment score of 2.5 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 6.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the company's share price in the near future. View News Stories for Aquestive Therapeutics.

Are investors shorting Aquestive Therapeutics?

Aquestive Therapeutics saw a decline in short interest during the month of July. As of July 31st, there was short interest totalling 356,400 shares, a decline of 19.1% from the June 30th total of 440,400 shares. Based on an average daily volume of 120,000 shares, the short-interest ratio is currently 3.0 days. Currently, 1.7% of the shares of the company are sold short. View Aquestive Therapeutics' Current Options Chain.

Who are some of Aquestive Therapeutics' key competitors?

What other stocks do shareholders of Aquestive Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aquestive Therapeutics investors own include Synergy Pharmaceuticals (SGYP), Roku (ROKU), Alibaba Group (BABA), TherapeuticsMD (TXMD), AbbVie (ABBV), Nucor (NUE), Amgen (AMGN), Exelixis (EXEL), NVIDIA (NVDA) and Opko Health (OPK).

Who are Aquestive Therapeutics' key executives?

Aquestive Therapeutics' management team includes the folowing people:
  • Mr. Keith J. Kendall, CEO, Pres & Director (Age 61)
  • Mr. John T. Maxwell, Sr. VP & CFO (Age 54)
  • Mr. Alexander Mark Schobel, Chief Innovation & Technology Officer (Age 60)
  • Mr. Daniel Barber, Sr. VP and Chief Strategy & Devel. Officer (Age 43)
  • Mr. Peter E. Boyd, Sr. VP of Operations & Value Delivery (Age 54)

When did Aquestive Therapeutics IPO?

(AQST) raised $60 million in an IPO on Wednesday, July 25th 2018. The company issued 4,000,000 shares at $14.00-$16.00 per share. BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow and JMP Securities were co-managers.

Who are Aquestive Therapeutics' major shareholders?

Aquestive Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (1.53%), Vanguard Group Inc. (1.25%), Northern Trust Corp (0.39%), Jacobs Levy Equity Management Inc. (0.34%), Wedbush Securities Inc. (0.28%) and Royal Bank of Canada (0.24%). Company insiders that own Aquestive Therapeutics stock include Alexander Mark Schobel, Daniel Barber, Douglas K Bratton, James S Scibetta, John T Maxwell, Keith J Kendall, Peter E Boyd and Theresa Wood. View Institutional Ownership Trends for Aquestive Therapeutics.

Which major investors are selling Aquestive Therapeutics stock?

AQST stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Vanguard Group Inc., Northern Trust Corp, Wells Fargo & Company MN and Bank of Montreal Can. View Insider Buying and Selling for Aquestive Therapeutics.

Which major investors are buying Aquestive Therapeutics stock?

AQST stock was bought by a variety of institutional investors in the last quarter, including Jacobs Levy Equity Management Inc., Wedbush Securities Inc., Royal Bank of Canada, Paloma Partners Management Co, Jane Street Group LLC, Canada Pension Plan Investment Board, JPMorgan Chase & Co. and Morgan Stanley. Company insiders that have bought Aquestive Therapeutics stock in the last two years include Alexander Mark Schobel, Daniel Barber, Douglas K Bratton, James S Scibetta, John T Maxwell, Keith J Kendall, Peter E Boyd and Theresa Wood. View Insider Buying and Selling for Aquestive Therapeutics.

How do I buy shares of Aquestive Therapeutics?

Shares of AQST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aquestive Therapeutics' stock price today?

One share of AQST stock can currently be purchased for approximately $3.85.

How big of a company is Aquestive Therapeutics?

Aquestive Therapeutics has a market capitalization of $96.37 million and generates $67.43 million in revenue each year. The company earns $-61,380,000.00 in net income (profit) each year or ($2.80) on an earnings per share basis. Aquestive Therapeutics employs 277 workers across the globe.View Additional Information About Aquestive Therapeutics.

What is Aquestive Therapeutics' official website?

The official website for Aquestive Therapeutics is http://www.aquestive.com/.

How can I contact Aquestive Therapeutics?

Aquestive Therapeutics' mailing address is 30 TECHNOLOGY DRIVE, WARREN NJ, 07059. The company can be reached via phone at 908-941-1900 or via email at [email protected]


MarketBeat Community Rating for Aquestive Therapeutics (NASDAQ AQST)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  87 (Vote Outperform)
Underperform Votes:  98 (Vote Underperform)
Total Votes:  185
MarketBeat's community ratings are surveys of what our community members think about Aquestive Therapeutics and other stocks. Vote "Outperform" if you believe AQST will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AQST will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/25/2019 by MarketBeat.com Staff

Featured Article: What Are Cryptocurrencies?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel